| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2156.4B | ¥2133.8B | +1.1% |
| Operating Income | ¥153.3B | ¥64.0B | +139.6% |
| Profit Before Tax | ¥172.6B | ¥100.1B | +72.4% |
| Net Income | ¥138.1B | ¥78.7B | +75.5% |
| ROE | 8.6% | 5.5% | - |
FY2025 full-year results (consolidated, IFRS): Revenue 215.6B yen (YoY +1.1%), Operating Income 15.3B yen (YoY +139.6%), Ordinary Income 6.9B yen (YoY +150.5%), Net Income 13.7B yen (YoY +75.5%). The company achieved substantial profit expansion despite modest revenue growth, with operating margin improving to 7.1% from 3.0% in the prior year, representing an increase of approximately 410 basis points. This marked improvement in profitability was driven primarily by segment mix optimization in the Industrial segment and cost structure improvements, though working capital efficiency deteriorated significantly with DSO reaching 134 days and inventory turnover extending to 147 days. Operating cash flow of 17.6B yen exceeded net income by 1.29x, demonstrating solid cash generation quality despite the working capital pressures.
Revenue increased 1.1% YoY to 215.6B yen, driven by divergent segment performance. The Industrial segment grew 5.1% to 136.8B yen, reflecting demand recovery in specialty pumps, aerospace CFRP products, and deep UV LED applications, particularly in North America and Europe markets. Conversely, the Medical segment contracted 5.3% to 78.9B yen due to challenging market conditions in dialysis equipment in Asia and competitive pricing pressures. Geographic revenue breakdown showed Japan at 70.7B yen (+1.3% YoY), Asia at 60.2B yen (-9.6%), North America at 49.7B yen (+6.9%), and Europe at 26.5B yen (+9.2%), indicating growth concentration in Western markets offset by Asia weakness.
Operating income surged 139.6% to 15.3B yen, with operating margin expanding from 3.0% to 7.1%. This improvement was primarily attributable to: (1) Industrial segment profit doubling to 13.5B yen from 7.3B yen driven by favorable product mix toward high-margin specialty pumps and aerospace components; (2) Medical segment profit increasing 51.0% to 6.1B yen from 4.0B yen despite revenue decline, suggesting effective cost management and pricing optimization; (3) Corporate unallocated expenses declining to 4.9B yen from 5.1B yen, reflecting improved overhead absorption. Cost of sales declined to 150.6B yen from 155.4B yen despite flat revenue, yielding gross profit margin expansion to 30.1% from 27.2%. SG&A expenses decreased to 50.1B yen from 51.7B yen, improving SG&A ratio to 23.2% from 24.2%.
Non-recurring factors included a 455M yen gain from subsidiary equity sales recorded in segment adjustments, and minimal impairment losses of 125M yen compared to 824M yen in the prior year, collectively contributing approximately 1.1B yen to operating income improvement. Finance income decreased to 2.5B yen from 3.8B yen, primarily due to reduced foreign exchange gains (FX impact -1.3B yen), while finance costs increased slightly to 1.1B yen from 1.0B yen reflecting higher interest expenses from increased borrowings. Equity method investment income declined to 575M yen from 768M yen. The gap between operating income (15.3B yen) and ordinary income (6.9B yen) of -8.4B yen appears inconsistent with typical Japanese GAAP ordinary income definition, suggesting potential data classification differences under IFRS reporting. Tax expense increased to 3.4B yen from 2.1B yen, yielding an effective tax rate of 20.0% on pre-tax profit of 17.3B yen, which represents a moderate tax burden.
This represents a revenue up/profit up pattern, with profit growth substantially outpacing revenue growth driven by operational leverage, segment mix improvement, and effective cost management.
The Industrial segment recorded revenue of 136.8B yen (+5.1% YoY) with operating income of 13.5B yen (+84.8% YoY), representing segment operating margin of 9.9% versus 5.6% in the prior year. This constitutes the core business with 63.4% of total revenue and 69.0% of segment profit. The substantial margin expansion was driven by favorable product mix with increased contribution from high-margin specialty pumps for semiconductor and energy applications, and aerospace CFRP components benefiting from civil aviation demand recovery. North America and Europe sales growth of 6.9% and 9.2% respectively supported pricing power and volume leverage.
The Medical segment generated revenue of 78.9B yen (-5.3% YoY) with operating income of 6.1B yen (+51.0% YoY), achieving segment operating margin of 7.7% versus 4.8% in the prior year. Despite revenue headwinds from dialysis equipment market saturation in Asia and competitive dynamics, the segment demonstrated strong cost discipline and operational efficiency improvements. The margin expansion suggests successful product rationalization, pricing adjustments on consumables (dialyzers, blood circuits), and streamlined distribution expenses.
Material margin differential exists between segments, with the Industrial segment operating margin of 9.9% exceeding Medical segment margin of 7.7% by 220 basis points. The Industrial segment's margin advantage reflects higher value-add in specialized industrial applications and aerospace components versus the more commoditized dialysis equipment market. Corporate costs allocated across segments totaled 4.9B yen, representing approximately 2.3% of consolidated revenue.
[Profitability] ROE of 9.2% represents the company's return generation on shareholder equity, with operating margin of 7.1% improved from 3.0% YoY (+410 basis points), and net profit margin of 6.4% compared to 3.7% in the prior year. The DuPont decomposition indicates ROE improvement was primarily driven by net profit margin expansion from operational leverage and cost control, with asset turnover of 0.60x and financial leverage of 2.24x. [Cash Quality] Cash and cash equivalents stood at 44.6B yen, providing coverage of short-term borrowings (8.7B yen) at 5.1x, though working capital quality deteriorated with DSO extending to 134 days from previous levels and inventory days reaching 147 days, resulting in cash conversion cycle of 211 days that constrains liquidity generation. [Investment Efficiency] Total asset turnover of 0.60x reflects moderate asset utilization, with capital expenditure of 5.1B yen representing 2.4% of revenue, indicating disciplined investment in manufacturing capacity and technology. [Financial Health] Equity ratio of 44.2% improved from 43.6% YoY, current ratio data unavailable from provided financials, but debt-to-equity ratio of 0.52x (total interest-bearing debt 82.6B yen versus equity 160.2B yen) demonstrates conservative leverage with debt-to-capital ratio of 34.0%, maintaining investment-grade financial flexibility.
Operating cash flow of 17.6B yen represents 1.29x of net income, confirming cash-backed earnings quality despite working capital headwinds. The cash generation from operations comprised pre-tax profit of 17.3B yen adjusted for non-cash items including depreciation and amortization of 11.2B yen, with working capital movements creating significant cash drains: trade receivables increased by 12.5B yen reflecting extended collection cycles (DSO 134 days), inventories rose 2.7B yen indicating stock buildup (DIO 147 days), while trade payables increased only 3.4B yen providing limited offset. Contract liabilities increased 2.6B yen contributing positively to operating cash flow. Tax payments of 2.3B yen and interest paid of 1.1B yen represent moderate cash outflows. Investing cash flow recorded net inflow of 133M yen, comprising capital expenditure of 5.1B yen for maintenance and growth investments in manufacturing facilities, offset by proceeds from subsidiary equity sales of 5.6B yen (non-recurring) and business divestiture proceeds of 610M yen. Financing cash flow showed net outflow of 9.8B yen, primarily from long-term debt repayments of 8.2B yen, dividend payments of 2.2B yen, share repurchases of 1.5B yen, and lease liability payments of 4.2B yen, partially offset by new long-term borrowings of 6.6B yen. Free cash flow of 17.8B yen (operating CF plus investing CF) demonstrates strong liquidity generation capacity, providing comfortable coverage of shareholder distributions and debt service obligations. Foreign exchange effects added 715M yen to cash balances, reflecting yen depreciation impact on overseas cash holdings.
Operating income of 15.3B yen versus pre-tax profit of 17.3B yen indicates net non-operating income contribution of approximately 2.0B yen, comprising finance income of 2.5B yen (including interest and dividend income, FX gains) less finance costs of 1.1B yen (interest expense), plus equity method investment income of 575M yen and net other income of 425M yen (other income 1.6B yen less other expenses 1.2B yen). Non-operating income represents approximately 1.2% of revenue, a modest level suggesting core operations drive profitability. Notable non-recurring items include the 455M yen gain from subsidiary equity sales recorded within segment adjustments and minimal impairment reversals, which collectively represent approximately 2.5% of operating income. Operating cash flow of 17.6B yen exceeding net income of 13.7B yen by 29% indicates healthy earnings quality from a cash perspective, though the substantial working capital deterioration (receivables +12.5B yen, inventories +2.7B yen) absorbed significant cash that would otherwise strengthen this metric. Depreciation and amortization of 11.2B yen represents a significant non-cash charge approximating 5.2% of revenue, reflecting capital intensity in industrial and medical equipment manufacturing. The divergence between net income growth of 75.5% and operating cash flow growth of 368.3% stems from extraordinary prior year tax payments that suppressed comparative operating CF, suggesting current period normalized cash generation. Accruals assessment shows income tax expense of 3.4B yen against tax payments of 2.3B yen, with deferred tax liabilities increasing to 9.3B yen from 3.1B yen, indicating tax-related timing benefits that may reverse in future periods. Overall earnings quality is satisfactory with cash-backed profits, though working capital management deterioration and the presence of modest non-recurring gains warrant monitoring for sustainability.
The company forecasts full-year revenue of 233.5B yen representing 8.3% growth from FY2025 actual of 215.6B yen, and operating income of 16.5B yen representing 7.6% growth from FY2025 actual of 15.3B yen. Current full-year results achieved 92.3% of revenue guidance and 92.9% of operating income guidance, indicating conservative initial projections that were nearly fulfilled. The operating income forecast of 16.5B yen implies operating margin of 7.1%, consistent with FY2025 achieved margin, suggesting management expects to sustain current profitability levels while growing top line. Forecast EPS of 199.19 yen compares to FY2025 actual EPS of 206.22 yen, implying expected net income of approximately 13.2B yen (based on average shares outstanding of 66.2M), representing a slight decline from FY2025 net income of 13.7B yen. This divergence between growing operating income and declining net income suggests expectations for higher tax burden, reduced non-operating income, or one-time charges in the forecast period. Forecast dividend of 25.00 yen per share represents a decrease from FY2025 implied annual dividend of 30.00 yen (15.00 interim + 15.00 year-end based on shareholder return data), yielding a forecast payout ratio of 12.5% on forecast EPS, down from reported 25.0% payout ratio in FY2025. This dividend reduction aligns with the expected net income decline and suggests management conservatism on distributable profits. The guidance reflects management's mid-term plan "NIKKISO 2028 - Toward a Healthier World" focusing on profitable growth through product innovation, geographic expansion, and operational excellence. No explicit order backlog data is disclosed, limiting forward revenue visibility assessment. Management assumptions likely incorporate continued recovery in industrial end-markets (semiconductor, energy, aerospace), stabilization of medical segment competitive dynamics, and sustained cost discipline, while factoring risks from foreign exchange volatility, geopolitical uncertainties, and supply chain pressures.
Annual dividend of 30.00 yen per share (15.00 interim + 15.00 year-end as implied from payout ratio and EPS data) compares to prior year levels, maintaining stable shareholder distributions. The payout ratio of 25.0% (reported) versus net income indicates conservative dividend policy preserving capital for growth investments and financial flexibility. Share repurchases totaling 1.5B yen were executed during the fiscal year, representing approximately 11.2% of net income and demonstrating management's commitment to shareholder returns through capital allocation flexibility. Total shareholder return combining dividends of 2.2B yen and buybacks of 1.5B yen equals 3.7B yen, representing a total return ratio of 27.1% relative to net income of 13.7B yen. This balanced approach between dividends and buybacks provides both income stability and capital efficiency optimization. The forecast dividend of 25.00 yen per share for the coming period represents a reduction from the current 30.00 yen, aligning with expected net income decline to approximately 13.2B yen (implied from forecast EPS of 199.19) and yielding forecast payout ratio of approximately 12.5%. The dividend reduction and lower payout ratio suggest management is prioritizing financial conservatism amid anticipated profitability normalization, while retaining capacity for strategic investments under the NIKKISO 2028 mid-term plan. Free cash flow of 17.8B yen provides ample coverage of current shareholder returns (3.7B yen) at 4.8x, supporting sustainability of distributions even with anticipated working capital pressures. However, persistent working capital deterioration (DSO 134 days, DIO 147 days) and elevated cash conversion cycle (211 days) present risks to future cash generation that could constrain total return capacity if not addressed through operational improvements in receivables collection and inventory management.
Working capital deterioration represents the most immediate financial risk, with days sales outstanding extending to 134 days and inventory turnover days reaching 147 days, resulting in a cash conversion cycle of 211 days that significantly constrains liquidity generation. Trade receivables increased 12.5B yen YoY, absorbing cash that would otherwise strengthen financial flexibility, while inventories rose 2.7B yen indicating potential demand-supply mismatches or product obsolescence risks. If collection efficiency and inventory management do not improve, operating cash flow generation could decline materially, potentially requiring increased external financing or constraining shareholder returns and growth investments. Quantitatively, a 20-day reduction in DSO would release approximately 11.9B yen in working capital, highlighting the magnitude of trapped liquidity.
Geographic and segment concentration risk emerges from the Industrial segment now representing 63.4% of revenue and 69.0% of segment profit, with particular exposure to North American aerospace and semiconductor end-markets that contributed disproportionately to recent growth. The Medical segment's 5.3% revenue decline in Asia markets (which contracted 9.6% overall) indicates competitive vulnerability in dialysis equipment. Economic slowdowns in North America or semiconductor industry cyclicality could significantly impact consolidated profitability, while further Asian medical market share erosion would undermine diversification benefits. The geographic revenue concentration in Japan (32.8%), Asia (27.9%), and North America (23.1%) creates multi-regional exposure risks.
Profitability sustainability risk arises from potential non-recurring profit contributors, including the 455M yen gain from subsidiary equity sales and the 699M yen reduction in impairment charges compared to prior year, which collectively represent approximately 7.0% of operating income. Additionally, the divergence between operating income growth (+139.6%) substantially exceeding revenue growth (+1.1%) implies exceptional operational leverage that may not persist at current operating rates. If revenue growth does not accelerate in line with guidance (+8.3% forecast) or if cost pressures resume, operating margins could compress from the current 7.1% toward historical averages, potentially disappointing investor expectations built on recent margin expansion. The company's guidance for operating income growth of only 7.6% versus revenue growth of 8.3% suggests management anticipates some margin normalization.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 9.2% demonstrates moderate return generation for a diversified industrial and medical equipment manufacturer, reflecting improved operational efficiency from the prior year's lower levels. Operating Margin 7.1% represents the company's current profitability positioning following substantial margin expansion from 3.0%, indicating successful operational leverage execution and segment mix optimization, though sustainability depends on maintaining cost discipline and favorable product mix. Net Profit Margin 6.4% reflects solid bottom-line efficiency after tax and non-operating items, improved from 3.7% in the prior period.
Financial Health: Equity Ratio 44.2% indicates moderate financial stability with balanced capital structure, providing adequate cushion for business cyclicality and investment flexibility. Debt-to-Equity Ratio 0.52x demonstrates conservative leverage policy, maintaining investment-grade financial profile with debt-to-capital ratio of 34.0%. The company's interest coverage appears comfortable with operating income of 15.3B yen substantially exceeding interest expense of 1.1B yen by approximately 14x, supporting financial resilience.
Efficiency: Asset Turnover 0.60x reflects moderate asset utilization efficiency for capital-intensive industrial and medical equipment manufacturing. Working capital efficiency deteriorated significantly with Cash Conversion Cycle extending to 211 days (DSO 134 days, DIO 147 days), representing an area of competitive disadvantage versus efficient industry operators that typically maintain CCC below 150 days through disciplined receivables management and just-in-time inventory practices. Inventory Turnover of 2.5x (365/147 days) suggests slower stock rotation compared to lean manufacturing benchmarks.
Growth: Revenue Growth YoY 1.1% indicates mature market positioning with modest organic expansion, below typical industry growth rates in specialty industrial equipment (3-5% range) and medical devices (4-6% range), reflecting mixed segment performance with Industrial growth offset by Medical contraction. Operating income growth of 139.6% represents exceptional profitability recovery, though includes non-recurring benefits and margin normalization from depressed prior year base.
※ Industry: Diversified Industrial and Medical Equipment Manufacturing, Comparison: Prior fiscal periods and general industry characteristics, Source: Proprietary analysis
Substantial margin expansion achieved in FY2025 demonstrates operational leverage potential when segment mix and cost management align favorably, with operating margin improving 410 basis points to 7.1% from 3.0% despite modest revenue growth. This improvement was driven by Industrial segment profit doubling through favorable product mix toward high-margin specialty pumps and aerospace CFRP components, and Medical segment margin expansion despite revenue decline through effective cost discipline. However, sustainability of current margin levels depends on maintaining favorable product mix, cost control discipline, and volume growth to absorb fixed costs. The company's guidance for operating margin to remain flat at 7.1% in the forecast period suggests management views current profitability as maintainable, though working capital pressures and potential cost inflation represent downside risks.
Working capital management deterioration represents a critical operational challenge requiring immediate attention, with DSO extending to 134 days and DIO reaching 147 days, resulting in cash conversion cycle of 211 days that materially constrains cash generation efficiency. Trade receivables increased 12.5B yen absorbing significant operating cash flow, while inventory buildup of 2.7B yen indicates potential demand planning or supply chain inefficiencies. Despite these headwinds, operating cash flow of 17.6B yen still exceeded net income by 1.29x, demonstrating underlying cash generation quality. Management must prioritize receivables collection acceleration and inventory optimization to release trapped working capital estimated at approximately 12-15B yen based on industry-standard CCC of 150 days, which would substantially enhance free cash flow available for shareholder returns and strategic investments under the NIKKISO 2028 mid-term plan.
Balanced capital allocation framework combining dividends and share repurchases demonstrates management's commitment to shareholder value creation, with total returns of 3.7B yen (27.1% of net income) comfortably covered by free cash flow of 17.8B yen. The forecast dividend reduction to 25.00 yen from 30.00 yen reflects financial conservatism ahead of anticipated profit normalization, preserving flexibility for mid-term plan investments in growth initiatives and technology development. Share repurchases of 1.5B yen provide additional value return mechanism while maintaining balance sheet strength with equity ratio of 44.2% and conservative debt-to-equity of 0.52x. The company retains capacity for sustained shareholder distributions and strategic M&A or organic investments, contingent on successful working capital management improvements and sustained profitability levels achieved in FY2025.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.